2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …

Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Objectives The aim of this study was to compare short dual antiplatelet therapy (DAPT) and
de-escalation in a network meta-analysis using standard DAPT as common comparator …

Aims Patients at high bleeding risk (HBR) represent a prevalent subgroup among those
undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a …

Acute coronary syndromes (ACS) are frequently reported in patients with coronavirus
disease 2019 (COVID‐19) and may impact patient clinical course and mortality. Although …

Owing to recent advances in early reperfusion strategies, pharmacological therapy,
standardized care, and the identification of vulnerable patient subsets, the prognosis of …

Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …